See today's BioWorld
To read the full story, subscribe or sign in.

Rapt scales back after zelnecirnon clinical hold

Nov. 11, 2024
By Lee Landenberger
Rapt Therapeutics Inc. has decided to shut down its zelnecirnon (RPT-193) program in asthma and atopic dermatitis, causing the company’s stock (NASDAQ:RAPT) to sharply decline Nov. 11.
BioWorld Clinical Regulatory Dermatologic Respiratory Small molecule U.S. FDA